Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Tyr Pharma's stock surged on positive data for pulmonary sarcoidosis treatment, but cash balance risk keeps investors ...

Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio. Headquartered in Switzerland, Windward Bio is a ...

Discover the top 19 most notable drugs approved by the FDA in 2024, including Dupixent for COPD and FluMist for self-administration. See the full list here.

A new era, where AI is at the centre of the drug discovery process is emerging, says Charlotte Deane, a professor of ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

Scotland has the highest rate of drugs deaths in Europe, with fatalities rising by 12 in a year to 1,172 drug-related deaths in 2023.

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

The U.S. FDA has provided advice for Tiakis Biotech's Phase 2 clinical trial of tiprelestat for pulmonary arterial ...

Tectonic's lead asset, TX45, is a long-acting Fc-relaxin fusion protein to treat group 2 pulmonary hypertension. Read why I'm ...